Nolatrexed

Nolatrexed is a quinazoline derivative that was developed as an antimetabolite for the treatment of various types of cancer. It is also known by its chemical name, Thymitaq, and was developed by the pharmaceutical company Zeneca.

History

Nolatrexed was first synthesized in the 1990s as part of a research program aimed at developing new chemotherapeutic agents. Early studies showed that it had potent antitumor activity in a variety of preclinical models.

Mechanism of Action

Nolatrexed works by inhibiting the enzyme thymidylate synthase, which is essential for DNA synthesis. By blocking this enzyme, Nolatrexed prevents cancer cells from replicating their DNA and thus inhibits their growth and proliferation.

Clinical Trials

Several clinical trials have been conducted to evaluate the efficacy and safety of Nolatrexed in patients with various types of cancer. However, the results have been mixed, and the drug has not been approved for use in any country.

Side Effects

Like all chemotherapeutic agents, Nolatrexed can cause a range of side effects. These can include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include myelosuppression, which is a decrease in the production of blood cells in the bone marrow.

Current Status

As of 2021, Nolatrexed is not currently approved for use in any country. However, research into its potential uses continues, and it is possible that it may be approved for use in the future.

See Also

• Chemotherapy
• Antimetabolite
• Thymidylate synthase